These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11418070)

  • 1. A mouse model for calculating the absorbed beta-particle dose from (131)I- and (90)Y-labeled immunoconjugates, including a method for dealing with heterogeneity in kidney and tumor.
    Flynn AA; Green AJ; Pedley RB; Boxer GM; Boden R; Begent RH
    Radiat Res; 2001 Jul; 156(1):28-35. PubMed ID: 11418070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mouse model for calculating cross-organ beta doses from yttrium-90-labeled immunoconjugates.
    Hui TE; Fisher DR; Kuhn JA; Williams LE; Nourigat C; Badger CC; Beatty BG; Beatty JD
    Cancer; 1994 Feb; 73(3 Suppl):951-7. PubMed ID: 8306284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry.
    Behr TM; Sharkey RM; Sgouros G; Blumenthal RD; Dunn RM; Kolbert K; Griffiths GL; Siegel JA; Becker WS; Goldenberg DM
    Cancer; 1997 Dec; 80(12 Suppl):2591-610. PubMed ID: 9406714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of the cross-organ beta dose method for tissue dosimetry in tumor-bearing mice treated with a 90Y-labeled immunoconjugate.
    Beatty BG; Kuhn JA; Hui TE; Fisher DR; Williams LE; Beatty JD
    Cancer; 1994 Feb; 73(3 Suppl):958-65. PubMed ID: 8306285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The nonuniformity of antibody distribution in the kidney and its influence on dosimetry.
    Flynn AA; Pedley RB; Green AJ; Dearling JL; El-Emir E; Boxer GM; Boden R; Begent RH
    Radiat Res; 2003 Feb; 159(2):182-9. PubMed ID: 12537523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
    Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Begent RH
    Cancer Biother Radiopharm; 2001 Oct; 16(5):391-400. PubMed ID: 11776756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings.
    Behr TM; Béhé M; Sgouros G
    Cancer Biother Radiopharm; 2002 Aug; 17(4):445-64. PubMed ID: 12396708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody and radionuclide characteristics and the enhancement of the effectiveness of radioimmunotherapy by selective dose delivery to radiosensitive areas of tumour.
    Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Bhatia J; Morris R; Begent RH
    Int J Radiat Biol; 2002 May; 78(5):407-15. PubMed ID: 12020430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonuniform absorbed dose distribution in the kidney: the influence of organ architecture.
    Green A; Flynn A; Pedley RB; Dearling J; Begent R
    Cancer Biother Radiopharm; 2004 Jun; 19(3):371-7. PubMed ID: 15285885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
    Konijnenberg MW; Bijster M; Krenning EP; De Jong M
    J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A five-compartment biokinetic model for
    Jeremic MZ; Matovic MD; Krstic DZ; Pantovic SB; Nikezic DR
    Med Phys; 2018 Dec; 45(12):5577-5585. PubMed ID: 30291717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorbed fractions for electrons and beta particles in spheres of various sizes.
    Siegel JA; Stabin MG
    J Nucl Med; 1994 Jan; 35(1):152-6. PubMed ID: 8271037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of beta-absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides.
    Miller WH; Hartmann-Siantar C; Fisher D; Descalle MA; Daly T; Lehmann J; Lewis MR; Hoffman T; Smith J; Situ PD; Volkert WA
    Cancer Biother Radiopharm; 2005 Aug; 20(4):436-49. PubMed ID: 16114992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
    Behr TM; Sgouros G; Stabin MG; Béhé M; Angerstein C; Blumenthal RD; Apostolidis C; Molinet R; Sharkey RM; Koch L; Goldenberg DM; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A volume-equivalent spherical necrosis-tumor-normal liver model for estimating absorbed dose in yttrium-90 microsphere therapy.
    Wu CH; Liao YJ; Lin TY; Chen YC; Sun SS; Liu YH; Hsu SM
    Med Phys; 2016 Nov; 43(11):6082. PubMed ID: 27806615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine S factors for liver, spleen, and kidney.
    Kolbert KS; Watson T; Matei C; Xu S; Koutcher JA; Sgouros G
    J Nucl Med; 2003 May; 44(5):784-91. PubMed ID: 12732681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the Application of Tissue-Specific Dose Kernels Instead of Water Dose Kernels in Internal Dosimetry: A Monte Carlo Study.
    Khazaee Moghadam M; Kamali Asl A; Geramifar P; Zaidi H
    Cancer Biother Radiopharm; 2016 Dec; 31(10):367-379. PubMed ID: 27996311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy.
    Emfietzoglou D; Kostarelos K; Sgouros G
    J Nucl Med; 2001 Mar; 42(3):499-504. PubMed ID: 11337529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation.
    Dahle J; Bruland OS; Larsen RH
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):186-92. PubMed ID: 18722269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.